Clinical and Multimodal Imaging Findings and Risk Factors for Ocular Involvement in a Presumed Waterborne Toxoplasmosis Outbreak, Brazil

Camilo Brandão-de-Resende, Helena Hollanda Santos, Angel Alessio Rojas Lagos, Camila Munayert Lara, Jacqueline Souza Dutra Arruda, Ana Paula Maia Peixoto Marino, Lis Ribeiro do Valle Antonelli, Ricardo Tostes Gazzinelli, Ricardo Wagner de Almeida Vitor, Daniel Vitor Vasconcelos-Santos

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 3121.

Release date: November 19, 2020; Expiration date: November 19, 2021

Learning Objectives

Upon completion of this activity, participants will be able to:

- Describe clinical and multimodal imaging findings at presentation and prevalence of and risk factors for ocular involvement in toxoplasmosis reported during an outbreak in 2015 in Gouveia, Brazil
- Determine recurrences and complications of toxoplasmosis reported during an outbreak in 2015 in Gouveia, Brazil
- Identify clinical implications of findings, course, and risk factors for ocular involvement in toxoplasmosis reported during an outbreak in 2015 in Gouveia, Brazil.

CME Editor

Amy J. Guinn, BA, MA, Copyeditor, Emerging Infectious Diseases. Disclosure: Amy J. Guinn, BA, MA, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Authors

Disclosure: Camilo Brandão-de-Resende, BEng, MD, PhD, and Daniel Vitor Vasconcelos-Santos, MD, PhD, have disclosed the following relevant financial relationships: co-founder/partner of Alsculapius Medicina Inteligente Ltda. Helena Hollanda Santos, MD, MSc; Angel Alessio Rojas Lagos, PhD; Camila Munayert Lara, MD; Jacqueline Souza Dutra Arruda, MD; Ana Paula Maia Peixoto Marino, PhD; Lis Ribeiro do Valle Antonelli, PhD; Ricardo Tostes Gazzinelli, PhD; and Ricardo Wagner de Almeida Vitor, PhD, have disclosed no relevant financial relationships.

Author affiliations: Universidade Federal de Minas Gerais, Belo Horizonte, Brazil (C. Brandão-de-Resende, H.H. Santos, A.A.R. Lagos, C.M. Lara, J.S.D. Arruda, R.W.A. Vitor, D.V. Vasconcelos-Santos); Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte (A.P.M.P. Marino, L.R.V. Antonelli, R.T. Gazzinelli).

DOI: https://doi.org/10.3201/eid2612.200227

1Presented in part at the 2015 American Uveitis Society Fall meeting, November 15, 2014, Las Vegas, Nevada, USA
In 2015, an outbreak of presumed waterborne toxoplasmosis occurred in Gouveia, Brazil. We conducted a 3-year prospective study on a cohort of 52 patients from this outbreak, collected clinical and multimodal imaging findings, and determined risk factors for ocular involvement. At baseline examination, 12 (23%) patients had retinochoroiditis; 4 patients had bilateral and 2 had macular lesions. Multimodal imaging revealed 2 distinct retinochoroiditis patterns: necrotizing focal retinochoroiditis and punctate retinochoroiditis. Older age, worse visual acuity, self-reported recent reduction of visual acuity, and presence of floaters were associated with retinochoroiditis. Among patients, persons >40 years of age had 5 times the risk for ocular involvement. Five patients had recurrences during follow-up, a rate of 22% per person-year. Recurrences were associated with binocular involvement. Two patients had late ocular involvement that occurred ≥34 months after initial diagnosis. Patients with acquired toxoplasmosis should have long-term ophthalmic follow-up, regardless of initial ocular involvement.

Toxoplasmosis is caused by *Toxoplasma gondii*, an obligate intracellular apicomplexan parasite that infects up to one third of the human population (1–4). Humans are mainly infected by ingesting tissue cysts in undercooked or raw meat or oocysts excreted in cat feces that contaminate water or food (1–4). Ocular disease is the major clinical repercussion in immunocompetent patients; toxoplasmosis is the leading cause of infectious posterior uveitis worldwide and can potentially lead to severe ocular complications (1,3,5,6). Although congenital toxoplasmosis more frequently leads to retinochoroiditis, postnatally acquired infection now is acknowledged as being associated with a large proportion of cases (2,3,6,7). Association between ocular toxoplasmosis and older age is not completely understood (8), but previous studies found increased prevalence of ocular involvement in persons >30 years of age (9,10).

Toxoplasmosis outbreaks are good opportunities to clarify clinical aspects of this complex disease because patients are infected at known times, by similar routes, and presumably by parasites of the same genotype (11–19). In 2015, an outbreak of presumed waterborne toxoplasmosis was reported in Gouveia, a small city of ~10,000 inhabitants in the center of the state of Minas Gerais in southeastern Brazil (20). Municipal, state, and federal health authorities investigated several cases of fever, malaise, weight loss, and lymphadenopathy. Recent toxoplasmic infection was eventually confirmed in 52 cases. All patients had the disease after drinking water from a single, presumably contaminated, source (20).

We performed complete ophthalmic examination and multimodal fundus imaging evaluation on all 52 patients. The objective of this study was to describe clinical and multimodal imaging findings and determine the prevalence of ocular involvement, incidence of recurrences and complications, and to analyze risk factors for ocular involvement in this cohort.

**Methods**

We used a prospective cohort approach to address our main goal. The study was approved by institutional review boards of René Rachou Research Center, Oswaldo Cruz Foundation (CAAE no. 37614314.7.3001.5091), and Federal University of Minas Gerais (CAAE no. 37614314.7.3001.5149). All patients provided written informed consent.

We defined a case as illness in a person in the city of Gouveia with a history of fever, headache, lymphadenopathy, asthenia, or myalgia during February 12–May 18, 2015. From 5,276 local health charts, a task force comprised of municipal, state, and federal health authorities identified 201 persons suspected of meeting case definition criteria. Before confirmation of toxoplasmosis, differential diagnosis was made with consultation of an infectious disease specialist and serologic tests for dengue fever, visceral leishmaniasis, and leptospirosis.

We contacted the 201 persons with suspected toxoplasmosis. We were able to reach 151 (75.1%) persons whom we subsequently interviewed and tested for toxoplasmosis. We defined confirmed cases of acute toxoplasmosis as persons having *T. gondii* IgM and low avidity IgG on enzyme-linked fluorescence assay by using Vidas Toxo IgM, IgGII, and IgG avidity assays (bioMérieux, https://www.biomerieux.com).

Among the 151 suspected cases interviewed and tested, 52 (34.4%) had serologic evidence of *T. gondii* IgM and low avidity IgG, indicating acute toxoplasmosis. We performed a complete ophthalmic examination on each of the 52 case-patients, including assessment of best-corrected visual acuity (VA), applanation tonometry, slit-lamp examination (SLE; biomicroscopy), and indirect ophthalmoscopy. All case-patients also underwent multimodal imaging evaluation, including fundus photography, reflectances, fundus autofluorescence, and spectral-domain optical coherence tomography (SD-OCT). For patients with confirmed ocular involvement, we also performed fluorescein angiography. We determined prevalence and incidence of ocular changes and clinical characteristics on the basis of clinical and multimodal imaging findings. All patients with ocular involvement received standard therapy for 35–45
days, which consisted of sulfadiazine (1 g 4×/d), pyrimethamine (25–50 mg/d), folinic acid (7.5 mg/d), and prednisone (40–60 mg/d). One patient was allergic to sulfa and was switched from sulfadiazine to clindamycin 300 mg 4×/d. Complete blood counts were monitored at baseline and every 2 weeks during treatment.

For 3 years, we conducted follow-up examinations on case-patients at 5–8-month intervals and conducted the same ophthalmic examination protocol periodically. We reexamined case-patients with active primary or recurrent retinochoroiditis 3–6 weeks after therapy, or more often, if needed. We defined severe ocular involvement as binocular or macular involvement, or extensive necrotizing retinochoroiditis of >3 disk diameter (DD).

We prospectively collected and stored in an electronic database clinical and ophthalmological data, including symptoms, best-corrected VA, applanation tonometry, SLE, indirect ophthalmoscopy, and multimodal imaging. We assessed best-corrected VA by using an early treatment of diabetic retinopathy study chart and reported results in logarithm of the minimum angle of resolution (logMAR) scale. Previous studies suggested increased prevalence of ocular involvement among patients ≥30 years of age and among patients ≥50 years of age (9,10). We also analyzed age ≥40 years at time of infection as a potential risk factor for occurrence and severity of ocular involvement.

We defined the time of primary infection for each case-patient as the time of ocular or systemic symptom onset. To calculate time intervals among persons with new active retinochoroidal lesions during follow-up, we assumed eye disease occurred when patients first noted ocular symptoms. For case-patients without ocular symptoms, we assumed eye disease occurred when consistent retinochoroidal lesions were identified. Among case-patients who displayed new retinochoroidal scars during follow-up exams, we assumed eye disease occurred when ocular symptoms first were perceived; if the case-patient did not notice any ocular symptoms, we assumed eye disease occurred in the time between the prior ocular examination and identification of the scar. We also noted the first instance of retinochoroidal recurrences in either eye.

We performed statistical analyses by using R version 3.5.2 (21) by nonparametric methods and considered p<0.05 statistically significant. We used Mann-Whitney-Wilcoxon test to compare continuous variables, including age, length of follow-up, and VA at baseline. We used the mid-p exact test to compare proportions between subgroups, such as age ≥40 years, sex, and presence of underlying conditions and symptoms. We reported continuous variables as median (interquartile range [IQR]) and proportions as no. (%). We estimated the 95% CI of relative risks by using a maximum-likelihood estimator and described the follow-up by using the rate of recurrence per person-year (22), rate of recurrence per person-month, and Kaplan-Meier survival plot (23). We estimated survival probability and cumulative risk for ocular involvement and ocular recurrence by using the Kaplan-Meier method and compared results by using a log-rank test (24,25).

Results

Baseline Examination
All 52 patients with serologic evidence of acute toxoplasmosis underwent a baseline examination in the first 4 months after onset of systemic symptoms; 40 (77%) patients had a baseline exam within the first month (Table 1). Median age at infection was 34 years (IQR 27–40 years); 8 (15.4%) patients were female and 44 (84.6%) were male. The most common systemic signs or symptoms were fever (52/52; 100%), headache (33/52; 63%), myalgia (30/52; 58%), and lymphadenopathy (8/52; 15%). Ocular symptoms were reported by 17 (32.6%) patients, among whom 9 (52.9%) reported recent VA decrease, 8 reported eye pain (47%), and 3 (17.6%) reported floaters.

At baseline, 12 (23%) patients had retinochoroiditis (Figure 1), 4 (33%) of whom had bilateral involvement and 2 (17%) of whom had macular involvement. Necrotizing lesions or scars were found in 10 (58%) patients; subtle punctate active lesions were found in 4 (33%) patients. Among 4 (33%) patients, we observed multiple necrotizing lesions or multifocal punctate active lesions in different retinal quadrants (Table 2). SLE revealed all 12 patients with toxoplasmic retinochoroiditis had inflammatory cells in the anterior vitreous; however, only 3 (25%) had inflammatory cells in the anterior chamber with standardization of uveitis nomenclature (SUN) grade ranging from 0.5+ to 3+. Intraocular pressure was within normal limits in all but 1 patient with granulomatous keratic precipitates and SUN of 3+ in the anterior chamber. Two (17%) patients with retinochoroiditis did not report any eye symptoms (Table 3).

We observed other fundus changes among patients with confirmed acute toxoplasmosis but without ocular involvement. One patient had un-specific focal retinal pigment epithelium (RPE) hyperplasia in 1 eye; a patient with nyctalopia had
Table 1. Characteristics and ocular signs and symptoms among patients with confirmed acute toxoplasmosis infection at baseline examination, Brazil*

| Characteristics                                      | Total, n = 52 | No ocular involvement, n = 40 | Ocular involvement, n = 12 | p value |
|------------------------------------------------------|---------------|--------------------------------|---------------------------|---------|
| Age at infection, y, median (IQR)†                  | 34 (27–40)    | 32 (22–38)                     | 43 (40–47)                | <0.01   |
| >40 years of age†                                    | 14 (27)       | 6 (15)                         | 9 (75)                    | <0.01   |
| Sex                                                  |               |                                |                           |         |
| M                                                    | 44 (84.6)     | 33 (82.5)                      | 11 (91.7)                 | 0.50    |
| F                                                    | 8 (15.4)      | 7 (17.5)                       | 1 (8.3)                   | 0.50    |
| Follow-up length, mo, median (IQR)                  | 36 (19–36)    | 36 (12–36)                     | 35 (24–37)                | 0.32    |
| Underlying conditions                                |               |                                |                           |         |
| Arterial hypertension                               | 7 (13.5)      | 4 (10.0)                       | 3 (25.0)                  | 0.23    |
| Diabetes mellitus                                    | 1 (1.9)       | 0                              | 1 (8.3)                   | 0.23    |
| General signs and symptoms                           |               |                                |                           |         |
| Fever                                                | 49 (94.2)     | 38 (95.0)                      | 11 (91.7)                 | 0.68    |
| Headache                                             | 33 (63.5)     | 25 (62.5)                      | 8 (66.7)                  | 0.81    |
| Myalgia                                              | 30 (57.7)     | 22 (55.0)                      | 8 (66.7)                  | 0.50    |
| Lymphadenopathy                                      | 8 (15.4)      | 7 (17.5)                       | 1 (8.3)                   | 0.50    |
| Ocular signs and symptoms                            |               |                                |                           |         |
| VA at baseline, logMAR, median (IQR)‡†              | 0.0 (0.0–0.0) | 0.0 (0.0–0.0)                  | 0.1 (0.0–0.6)             | 0.01    |
| Eye pain                                             | 8 (15.4)      | 5 (12.5)                       | 3 (25.0)                  | 0.33    |
| Self-reported recent reduction of VA†                | 10 (19.2)     | 1 (2.5)                        | 9 (75.0)                  | <0.01   |
| Floaters†                                            | 3 (5.7)       | 0                              | 3 (25.0)                  | 0.01    |

*Values are no. (%), except as indicated. Mann-Whitney-Wilcoxon test was used to compare continuous and the mid-p exact tests for proportions between subgroups. IQR, interquartile range; logMAR, logarithm of the Minimum Angle of Resolution scale; VA, visual acuity.
†Statistical significant at α = 5%.
‡For visual acuity baseline, binocular involvement was considered the worst VA.

bilateral optic disc pallor, vascular attenuation and RPE changes consistent with retinitis pigmentosa; another patient with severe systemic arterial hypertension had bilateral nerve-fiber layer infarcts. One patient with ocular toxoplasmosis in 1 eye had findings consistent with Leber miliary aneurysms in the contralateral eye.

Among the 12 patients with ocular disease at baseline, 9 (75%) had severe ocular involvement, defined by binocular, macular, or extensive (>3 DD) necrotizing retinochoroiditis. Among 9 patients with severe ocular involvement, the median age was 43 years (IQR 40–47 years); among 3 patients without severe ocular involvement the median age was 31 years (IQR 29–38 years), but the difference was not statistically significant (p = 0.14).

Age, self-reported recent reduction of VA, presence of floaters, and greater reduction in VA were associated with ocular involvement at baseline (Table 1). Among patients with ocular involvement, the median age at infection was 43 years (IQR 40–47 years) vs. 31 years (IQR 22–38 years) for patients without ocular involvement (p = 0.02); 9 (75%) patients with ocular involvement were ≥40 years of age at infection compared with 6 (15%) patients without ocular involvement (relative risk [RR] = 5.0, 95% CI 2.2–11.2; p<0.01).

Among these same subgroups, median logMAR VA at examination was 0.1 (IQR 0.0–0.6) for patients with ocular involvement compared with 0.0 (0.0–0.0) for patients without ocular involvement (p = 0.01).

Multimodal imaging revealed 2 distinct patterns of active retinochoroiditis: the typical pattern of focal necrotizing retinochoroiditis and punctate retinochoroiditis. Necrotizing retinochoroiditis subsequently left a variably pigmented scar and was more extensive in some cases, simulating a viral retinitis (Figure 2). Punctate retinochoroiditis displayed a much more subtle pattern, which was not seen as
patterns of retinochoroiditis seen in multimodal imaging among patients with toxoplasmosis treated with antiparasitic drugs and oral corticosteroids, Brazil*

| Type of lesion, fundus imaging modality | Patterns of retinochoroiditis | Active phase, before treatment | Cicatricial phase, after treatment |
|----------------------------------------|-------------------------------|--------------------------------|-----------------------------------|
| Focal necrotizing retinochoroiditis     | Dense focal retinal whitening with indistinct borders, associated with overlying vitreous haze | Initially hypopigmented retinochoroidal scar, but frequently evolving with variable degree of pigmentation and subretinal fibrosis or preretinal gliosis |
| Fundus photo or examination             | Subtle hypo- or hyper-autofluorescence changes at the level of the active lesion; near infrared reflectance can indicate active focus but not as remarkably as red-free reflectance | Increased autofluorescence signal in the first weeks, then hypo-autofluorescence at the level of the scar after several months; scars less clearly delineated by near-infrared than red-free reflectance, but both reveal retinal wrinkling in the presence of epiretinal membrane |
| SD-OCT                                 | Focal full-thickness hyper-reflectivity and disorganization of retinal layers indicating necrotizing retinitis; surrounding retinal thickening, signaling edema; numerous overlying hyper-reflective dots at the vitreous indicating vitreal inflammatory cell exudate; and underlying fusiform choroidal thickening, with loss of stromal/luminal pattern indicating reactive choroiditis | Autofluorescence and reflectance changes are minimal or absent |
| FAF reflectances                        | Early hypofluorescence, with progressive hyperfluorescence and late leakage at the retinochoroiditis lesion; reactive changes, including hyperfluorescence, of optic disc indicating edema; staining of venular walls, signaling periphlebitis | Normal or showing minimal punctate window defects |
| Punctate retinochoroiditis              | Multiple subtle, indistinct, or confluent gray-whitish punctate retinal infiltrates with minimal vitreous haze | Very subtle changes in retinal reflex, sometimes with minor hypopigmentation, but frequently with no apparent abnormality |
| Fundus photo or examination             | Multifocal hyper-reflectivity at the inner retinal layers, demonstrating retinitis, occasionally extending to deeper layers, with surrounding retinal thickening (edema); numerous overlying hyper-reflective dots indicating vitreal inflammatory cell exudate, along with thickening and shallow detachment of the posterior hyaloid; mild choroidal thickening without apparent major change in reflectivity | Frequent normalization of the retinal architecture, sometimes with mild disruption of outer retinal layers or retinal pigment epithelium; normalization of choroidal thickening; marked decrease in the number of overlying vitreal hyper-reflective dots and frequent tent-like focal detachment of the less-thickened overlying posterior hyaloid |
| SD-OCT                                 | Subtle hypo- or hyper-autofluorescence changes at the level of the punctate active lesions; near-infrared reflectance can show changes at the area of active foci but not as remarkably as red-free reflectance | Autofluorescence and reflectance changes are minimal or absent |
| FAF reflectances                        | Progressive but mild hyperfluorescence or late leakage at the site of punctate lesions; reactive changes, including hyperfluorescence of optic disc, demonstrating edema; staining of venular walls indicating periphlebitis | Normal or showing minimal punctate window defects |
| FFA                                    | Early hypofluorescence, with progressive hyperfluorescence and late leakage at the retinochoroiditis lesion; reactive changes, including hyperfluorescence, of optic disc indicating edema; staining of venular walls, signaling periphlebitis | Normal or showing minimal punctate window defects |

*FAF, fundus autofluorescence; FFA, fundus fluorescein angiography; SD-OCT, spectral-domain optical coherence tomography.

easily on fundus examination, but was nicely delineated by SD-OCT (Figure 3). All 12 patients with toxoplasmic retinochoroiditis promptly responded to antiparasitic treatment; 11 received standard therapy with sulfadiazine, pyrimethamine, and folic acid, supplemented with oral prednisone; 1 had clindamycin instead of sulfadiazine because of sulfa allergy. All 12 patients had resolution of intraocular inflammation within 5–6 weeks. However, the pattern of retinochoroiditis resolution differed between patients with focal necrotizing retinochoroiditis and those with punctate retinochoroiditis (Table 2).

**Follow-up Examinations**

Among all 52 patients in the cohort, the median length of follow-up after infection was 36 months (IQR 19–36 months); most (47; 90%) patients were followed for >6 months. Among the 12 patients with ocular involvement at baseline examination, 5 (42%) had recurrent retinochoroiditis during
follow-up examinations (Figure 1). The median time for first recurrence was 11 months after starting standard therapy for the first episode of ocular involvement, and the 5 patients had recurrences at 2, 9, 11, 12, and 22 months (Table 3). All 5 reported adequate treatment adhesion.

Rate of recurrence of retinochoroiditis among the 12 patients with ocular involvement at baseline was 22% per person-year (1.8% per person-month). All patients with binocular involvement (n = 4) had recurrent lesions during the follow-up period compared with only 13% (1/8) of patients with monocular involvement (RR = 8.0, 95% CI 1.3–50.0; p = 0.01). Rate of recurrence was 8.5% per person-month among patients with binocular involvement and 0.4% per person-month among the patients

### Table 3. Ocular characteristics, recurrences, and complications of patients with ocular involvement from toxoplasmosis, Brazil*

| Age, y/sex | Baseline eye examination | Follow-up findings | Complications | Last VA, mo; result |
|------------|--------------------------|--------------------|---------------|---------------------|
| 38/M†      | Bilateral VA 0.0; SLE, AV cells and AC cells (0.5+/4+); FE, multifocal PR and peripheral large FNR | 1 OD recurrence; month 2, satellite active lesion | None | 21; 0.0 OU |
| 47/M†      | Bilateral VA 0.2; SLE, AV cells; FE, peripheral large FNR | 1 OD recurrence; month 22, new peripheral scar | Month 22, epiretinal membrane OD | 34; 0.0 OU |
| 40/M†      | Bilateral VA 0.0; SLE, AV cells; FE, multifocal PR | Multiple recurrences OU; months 11, 21, and 24, active peripheral lesions; month 27, active peripheral lesion OS | Month 21, epiretinal membrane OD; month 27, rheumatogenous RD OS | 36; 0.0 OD; 0.8 OS |
| 48/M†      | Bilateral VA 2.1; SL, EAV cells; FE, macular FNR | 2 recurrences OS; new peripheral scar in months 12 and 15 | Month 9, epiretinal membrane OD; month 34, epiretinal membrane OS | 34; 1.9 OD; 0.4 OS |
| 43/M†      | Unilateral VA 0.0; SLE, normal; FE, Leber miliary aneurysms | – | None | 36; 0.1 OS |
| 27/M       | Unilateral VA 0.0; SLE, AV cells; FE, PR | – | None | 23; 0.0 OD |
| 42/M†      | Unilateral VA 0.5; SLE, granulomatous KP, AC cells (3+/4+); AV cells; IOP, 28 mmHg; FE, peripheral large FNR | 1 recurrence OD; month 9, multiple active peripheral lesions OD | Baseline transient IOP elevation OD, 28mmHg | 24; 0.0 OD |
| 31/M       | Unilateral VA 0.0; normal SLE and FE | – | None | 8; 0.0 OS |
| 50/M†      | Unilateral VA 0.5; SLE, AV cells; FE, peripheral large FNR | – | Month 6, posterior vitreous detachment OD | 37; 0.0 OD |
| 47/F†      | Unilateral VA 1.6; SLE, AV cells; FE, macular FNR | – | None | 37; 1.9 OD |
| 40/M†      | Unilateral VA 0.0; SLE, AV cells; FE, peripheral large FNR | – | None | 37; 0.0 OD |
| 45/M       | Unilateral VA 0.0; SLE, AV cells; FE, PR | –s | None | 37; 0.0 OD |
| 15/M‡      | NA | Late ocular involvement; OD VA 0.1; month 34, new peripheral scar | None | 34; 0.1 OD |
| 28/F‡      | NA | Late ocular involvement; OD VA 0.0; month 37, peripheral FNR | None | 39; 0.0 OD |

*Age represents age at detection of first ocular lesion or scar. AC cells, grading of anterior chamber cells according to Standardization of Uveitis Nomenclature (SUN) working group (29); AV cells, anterior vitreous cells; FE, fundus examination; FNR, focal necrotizing retinochoroiditis, large FNR is >3 disk diameters; IOP, intraocular pressure; KP, keratic precipitates; NA, not applicable; OD, oculus dexter (right eye); OS, oculus sinister (left eye); OU, oculus uterque (both eyes); PR, punctate retinochoroiditis; RC, retinochoroiditis; RD, retinal detachment; SLE, slit-lamp examination; VA, visual acuity (log MAR); –, no recurrence or no new lesion.
†Patients with severe ocular involvement, including binocular, macular, or extensive necrotizing retinochoroiditis (>3 disk diameters).
‡Patients with initial normal ophthalmic examination.
with monocular involvement (log-rank \( p = 0.01 \); Figure 4) (24,25).

Among patients without ocular involvement at baseline, 2/40 (5\%) had late ocular involvement. A 15-year-old boy had a new peripheral scar in his right eye (VA 0.1) 34 months after infection, referring a transient VA reduction that started 3 months earlier; the patient recovered spontaneously after a couple of weeks. A 28-year-old woman had a peripheral active lesion in her right eye (VA 0.0) at her 37-month follow-up examination but had no other ocular symptoms (Figure 5).

Overall, 14/52 (27\%) patients had ocular involvement at some point during the study. The rate of ocular involvement was 16\% per person-year (1.3\% per person-month).

**Complications and Visual Outcomes**

Among the 16 eyes (15\%) of 12 patients (23\%) with retinochoroiditis at baseline, ocular complications developed in 7 eyes (44\%) of 5 patients (42\%) during follow-up; 2 patients had complications in both eyes. Four (25\%) eyes had epiretinal membranes develop, detected at 9-, 21-, 22-, and 34-month follow-up visits. One (6\%) eye had rhegmatogeneous retinal detachment at the 27-month follow-up, which required pars plana vitrectomy. One (6\%) eye had transient intraocular pressure elevation at baseline, and 1 (6\%) had posterior vitreous detachment detected at the 6-month follow-up visit.

Among patients with retinochoroiditis at baseline, 4 (25\%) eyes among 3 (25\%) patients had logMAR VA >0.3 at the last follow-up examination. Two eyes had macular involvement at baseline examination and a final VA of 1.9; an epiretinal membrane developed in 1 eye (final VA 0.4), and rhegmatogeneous retinal detachment developed in the other, which underwent pars plana vitrectomy (final VA 0.8).

**Discussion**

We investigated ocular involvement of 52 patients with serologically confirmed acute toxoplasmosis acquired in a presumed waterborne outbreak. We described clinical and multimodal imaging findings and determined the prevalence of retinochoroiditis,
the incidence of recurrences and complications, and analyzed risk factors for ocular involvement.

In addition to the standard pattern of necrotizing retinochoroiditis, multimodal imaging revealed a distinct pattern of punctate retinal infiltrates (Figure 3), which might be overlooked if the retina is not examined carefully. This pattern also has been reported in neonates with congenital toxoplasmosis (5) and might represent the result of the primary parasite insult to the retina before a more robust immune response develops.

In this study, 12 (23%) patients displayed toxoplasmic retinochoroiditis at baseline examination; 14 (27%) had ocular involvement at some point during the study (Table 3), a rate of 16% per person-year. Variable rates of ocular involvement have been reported in toxoplasmosis outbreaks. For instance, risk for ocular involvement was 31% during the first 10.5 months after the Santa Isabel do Ivaí outbreak in Paraná, Brazil during 2001–2002 (15), and 21% after a mean follow-up of 114 weeks in an outbreak in Victória, British Columbia, Canada in 1995 (13,14).

As expected, eye symptoms, particularly self-reported recently decreased VA and floaters, were associated with ocular involvement, suggesting that clinicians should inquire about symptoms routinely during and after an outbreak. Nevertheless, 2/12 (16.6%) patients had retinochoroiditis at baseline in the absence of symptoms, reinforcing the importance of examining the eyes of every patient with confirmed acute T. gondii infection.

Older age was frequently associated with a higher risk for ocular involvement at baseline and patients ≥40 years of age at the time of infection had a 5 times greater risk for retinochoroiditis than younger patients. Patients in the subgroup with ocular involvement were much older than patients in the subgroup without ocular involvement, consistent with reports in other studies. In a study from the Netherlands, most patients with serologic evidence of recently acquired ocular toxoplasmosis were older, with a mean age of 50.6 years (26). A study from Brazil found age was a major risk factor for ocular involvement, with higher prevalence in patients ≥50 years of age, and ≥50% of patients >60 years of age had ocular involvement (10). Another study from Brazil found that persons >30 years of age with recently acquired T. gondii infection were more likely to have ocular involvement by the time of study enrollment (9).

At baseline examination, 75% (9/12) of patients with toxoplasmic retinochoroiditis in our study had severe ocular involvement, defined by large (>3 DD)
necrotizing, macular, or bilateral retinochoroiditis (Figure 2). The median age of the 9 patients with severe ocular involvement (43 years of age) was higher than the median age of the 3 patients with less severe disease (31 years of age), but the differences were not statistically significant, probably because of the small number of patients in each subgroup. These findings also are in line with the literature (8), agreeing with 2 previous studies focusing on ocular toxoplasmosis in patients ≥50 years of age (median 67.5 years) in which 22/34 (64.7%) patients had severe disease, defined as either multiple active lesions, large lesions (>3 DD), or prolonged disease (duration >8 weeks) (27,28). Another possible explanation for the higher rate and severity of ocular involvement in our cohort is involvement of a virulent atypical T. gondii strain. However, this possibility remains elusive because parasite isolation for subsequent genotyping was not successful in the presumably contaminated water source, or in blood samples of patients with serologically confirmed infection (20).

Recurrence of retinochoroiditis was associated with bilateral ocular involvement at initial examination (Figure 4). One possible explanation is that patients with bilateral lesions at initial examination might have had a higher parasite load systemically and in the retina, leading to an increased risk for local reactivation. This finding also might have been associated with some degree of subclinical immune dysfunction in these cases.

The most common complication was epiretinal membrane development in 25% of eyes with retinochoroiditis, a finding consistent with a transversal study including 248 patients with acquired toxoplasmosis in India, which also reported development of epiretinal membranes at 25.1% (12). At the last follow-up examination 3/12 (25%) patients with retinochoroiditis had logMAR VA >0.3, one of them in both eyes. Complications underlying this visual impairment included unilateral macular involvement at baseline in 2 patients (VA 1.9) and other late complications, including 1 eye with an epiretinal membrane (VA 0.4), and the other with a rhegmatogenous retinal detachment (VA 0.8 after pars plana vitrectomy).

In addition to the 4 patients who developed recurrences of retinochoroiditis at 2, 9, 11, 12, or even at 22 months of follow-up, 2 patients without retinochoroiditis had new primary retinal lesions detected ≥34
months of follow-up (Figure 5). This finding highlights the need for long-term ophthalmologic follow-up in patients with postnatally acquired toxoplasmosis, regardless of previous ocular involvement.

This study has some limitations. We only considered symptomatic patients as having suspected cases of acute toxoplasmosis, and that might represent only a small portion of infected persons; several asymptomatic persons probably were not included, and this selection bias might justify, at least in part, the high prevalence of ocular changes. However, selecting for symptomatic cases has been the rule in most investigations of outbreaks of toxoplasmosis because serologic survey of all persons in affected areas is difficult. Finally, incidence calculations were based on few events, especially within subgroups of cases with ocular involvement, and some statistical tests were underpowered, such as the comparison of age in relation to severity of ocular involvement.

Despite the limitations, our study provides objective documentation of ocular changes in the context of a toxoplasmosis outbreak. By using multimodal imaging, we were able to characterize more subtle lesions, such as punctate retinchoroiditis among 33% of cases with ocular involvement. By comparison, previous reports of ophthalmic assessment of patients during outbreaks mostly were based on indirect ophthalmoscopy alone. Among 52 patients with confirmed infection, 47 (90%) had ≥6 months of follow-up; the median length for follow-up was 36 months, which enabled us to estimate the incidence of new lesions, recurrences, and complications during a relatively long period. We noted a substantial prevalence of early ocular involvement, with recurrences and new lesions occurring up to 39 months after infection. Thus, patients diagnosed with toxoplasmosis should receive long-term ophthalmic follow-up, regardless of initial ocular involvement. In addition, older patients had higher risk for ocular involvement, possibly reflecting age-related changes in the immune system, which could predispose persons ≥40 years of age to more severe disease.

Acknowledgments
The authors thank the teams from the Brazilian Ministry of Health, especially Juliane Malta; from the State Secretary of Health of Minas Gerais, especially Marcela Lencine Ferraz; and from the Secretary of Health of Gouveia, especially Leticia Miranda, for participation and support. D.V.V.S. is supported in part by the National Council for Scientific and Technological Development, Brazil (research productivity scholarship no. 313293/2018-0) and received lecture fees from Abbvie.

About the Author
Dr. Brandão-de-Resende is an engineer and ophthalmologist and recently earned his PhD at the Federal University of Minas Gerais, Brazil. His research interests encompass uveitis, glaucoma, and applications of machine learning and artificial intelligence in ophthalmology.

References
1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363:1965–76. https://doi.org/10.1016/S0140-6736(04)16412-X
2. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136:973–88. https://doi.org/10.1016/j.ajo.2003.09.040
3. Vasconcelos-Santos DV. Ocular manifestations of systemic disease: toxoplasmosis. Curr Opin Ophthalmol. 2012;23:543–50. https://doi.org/10.1097/ICU.0b013e328358baf5
4. Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, et al. The One Health approach to toxoplasmosis: epidemiology, control, and prevention strategies. EcoHealth. 2019;16:378–90. https://doi.org/10.1007/s10393-019-01405-7
5. Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1–17. https://doi.org/10.1016/S0002-9394(03)01319-9

6. Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, Oréfice F, Queiroz-Andrade GM, Carellos EVM, et al. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009;116:2199–2205.e1. https://doi.org/10.1016/j.ophtha.2009.04.042

7. Arantes TE, Silveira C, Holland GN, Muccioli C, Yu F, Jones JL, et al. Ocular involvement following postnatally acquired Toxoplasma gondii infection in southern Brazil: a 28-year experience. Am J Ophthalmol. 2015;159:1002–12.e2. https://doi.org/10.1016/j.ajo.2015.02.015

8. Holland GN. Ocular toxoplasmosis: the influence of patient age. Mem Inst Oswaldo Cruz. 2009;104:351–7. https://doi.org/10.1590/S0074-02762009000200031

9. Dadgostar H, Silveira C, Jones JL, Lee G, Muccioli C, Belfort R Jr, et al. Risk factors for ocular toxoplasmosis among individuals recently infected by Toxoplasma gondii in Southern Brazil. In: Abstracts of the Association for Research in Vision and Ophthalmology annual meeting. Invest Ophthalmol Vis Sci. 2008;49:S529.

10. Portela RW, Bethony J, Costa MI, Gazzinelli A, Vitor RW, Hermeto FM, et al. A multi-household study reveals a positive correlation between age, severity of ocular toxoplasmosis, and levels of glycoinositolphospholipid-specific immunoglobulin A. J Infect Dis. 2004;190:175–83. https://doi.org/10.1086/421505

11. Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Oréfice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9:55–62. https://doi.org/10.3201/eid0901.020160

12. Balasundaram MB, Andavar R, Palaniswamy M, Venkatapathy N. Outbreak of acquired ocular toxoplasmosis involving 248 patients. Arch Ophthalmol. 2010;128:28–32. https://doi.org/10.1001/archophthalmol.2009.354

13. Bowie WR, King AS, Werker DJ, Isaac-Renton JL, Bell A, Eng SB, et al.; The BC Toxoplasma Investigation Team. Outbreak of toxoplasmosis associated with municipal drinking water. Lancet. 1997;350:173–7. https://doi.org/10.1016/S0140-6736(96)11055-3

14. Burnett AJ, Shortt SG, Isaac-Renton J, King A, Werker D, Bowie WR. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology. 1998;105:1032–7. https://doi.org/10.1016/S0161-6420(98)96004-3

15. Silveira C, Muccioli C, Holland GN, Jones JL, Yu F, de Paula A, et al. Ocular involvement following an epidemic of Toxoplasma gondii infection in Santa Isabel do Ivaí, Brazil. Am J Ophthalmol. 2015;159:1013–21.e3. https://doi.org/10.1016/j.ajo.2015.02.017

16. Teutsch SM, Juranek DD, Sulzer A, Dubey JP, Sikes RK. Epidemic toxoplasmosis associated with infected cats. N Engl J Med. 1979;300:695–9. https://doi.org/10.1056/NEJM197903290301302

17. Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol. 1973;57:1–17. https://doi.org/10.1136/bjo.57.1.1

18. Benenson MW, Takaufuji ET, Lemon SM, Greenup RL, Sulzer AJ. Oocyst-transmitted toxoplasmosis associated with ingestion of contaminated water. N Engl J Med. 1982;307:666–9. https://doi.org/10.1056/NEJM198209093071107

19. Akstein RB, Wilson LA, Teutsch SM. Acquired toxoplasmosis. Ophthalmology. 1982;89:1299–302. https://doi.org/10.1016/S0161-6420(82)34629-1

20. Malta JMAS, Cabral CM, Nóbrega AA, Leite PL, de Souza Alves RM, Almeida SML, et al. Outbreak of toxoplasmosis in the municipality of Gouveia, Minas Gerais [in Portuguese]. J Health Biol Sci. 2019;7:233–41. https://doi.org/10.12662/2317-3076jhs.v7i3.2375.p233-241.2019

21. R: a language and environment for statistical computing. 2017, Vienna, Austria: R Foundation for Statistical Computing [cited 2020 Feb 2]. https://www.r-project.org

22. Becker S. A comparison of maximum likelihood and Jewell’s estimators of the odds ratio and relative risk in single 2 x 2 tables. Stat Med. 1989;8:987–96. https://doi.org/10.1002/sim.4780080809

23. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol. 2005;139:900–5. https://doi.org/10.1016/j.ajo.2004.12.009

24. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biomietrika. 1982;69:553–66. https://doi.org/10.1093/biomet/69.3.553

25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

26. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:886–98. https://doi.org/10.1016/S0161-6420(02)00990-9

27. Labalette P, Delhaes L, Margaron F, Fortier B, Rouland JF. Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol. 2002;133:506–15. https://doi.org/10.1016/S0002-9394(02)01324-7

28. Johnson MW, Greven GM, Jaffe GJ, Sudhalkar H, Vine AK. Atypical, severe toxoplasmic retinochoroiditis in elderly patients. Ophthalmology. 1997;104:48–57. https://doi.org/10.1016/S0161-6420(97)30362-5

29. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16. https://doi.org/10.1016/j.ajo.2005.03.057

Address for correspondence: Daniel Vitor Vasconcelos-Santos, Av. Alfredo Balena 190, Sala 199, Belo Horizonte, MG 30190-090, Brazil. email: dvitor@ufmg.br